Wayne State University's Center for Emerging and Infectious Diseases and Office of Faculty Affairs & Professional Development welcomes all members of our community to join us for a special interactive discussion on Clostridiodes difficile infection(CDI) and the role of Live Biotherapeutic Products: 

CDI accounts for more than half a million cases annually in the United States. Recurrent CDI is particularly challenging to treat. With the discovery and approval of several Live Biotherapeutic products, we aim to provide guidance on the use of LBPs in the future during this session.

Learning Objectives

• Changes in Epidemiology and testing for C difficile infection
• Newer antibiotic and antibody regimens for CDI
• Incorporating FDA approved microbiome based therapies into clinical practice

Moderator(s):

Teena Chopra MD, MPH, Assistant Dean, Faculty Development and Coaching, Clinical Professor and Director of Epidemiology and Antibiotic Stewardship

Guest Speaker(s):

Paul Feuerstadt MD, FACG, AGAF, Dr. Paul Feuerstadt (“Foyer” “stat”) is a gastroenterologist practicing at the PACTGastroenterology Center. He is an assistant Clinical Professor of Medicine at the Yale University School of Medicine. He graduated from the University of Pennsylvania undergraduate and went on to attend Weill Medical College of Cornell University and he remained at New York Presbyterian Hospital-Cornell Medical Center for residency as well. He moved on to the Montefiore Medical Center of the Albert Einstein College of Medicine for his fellowship in Gastroenterology and hepatology.

Dr. Feuerstadt’s focuses include intestinal ischemia, the microbiota, C. difficile infection, acute and chronic changes in bowel habits. He has been a principal investigator on numerous clinical trials in these spaces. Within his practice he is very active in research, teaching and volunteer work locally and nationally for disease and discipline specific initiatives.Dr. Feuerstadt has authored and co-authored many manuscripts and textbook chapters. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally and also working with the fellows in the Division of Digestive Disease at Yale-New Haven Hospital. His clinical practice at the PACT Gastroenterology Division is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease.

Sahil Khanna, M.B.B.S., M.S., Dr. Sahil Khanna is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. He completed Medical School at the All India Institute of Medical Sciences, New Delhi; Post Doctoral Research at University of California San Diego, CA; Residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. He also completed Masters in Clinical and Translational Sciences at Mayo Clinic. His interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridioides difficile, an arena in which he has had over 150 publications and numerous presentations. He is directing the Consultative Gastroenterology Interest group, C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at Mayo Clinic, Rochester, MN. He has won numerous awards including the Miles and Shirley Fiterman Award, Mayo Brothers Distinguished Fellowship Award, Donald C. Balfour Mayo Clinic Alumni Association Research Award, amongst others.  

Planning Committee Members: Basim Dubaybo, M.D. (Activity Director), Kate Laimbeer, and Kailah Weatherspoon have no commercial/financial relationships.

Speakers: Commercial Relationships-All relevant commercial relationships with ineligible companies as defined by the ACCME have been mitigated.

Teena Chopra, MD, MPH

• Pfizer, Cepheid, Abbvie, Ferring – Speaker and Consultant

 Paul Feuerstadt , MD

• Ferring Pharmaceuticals – Speakers bureau, Consulting, Advisory Board
• SERES Therapeutics – Consulting, Advisory Board
• Merck and Co. – Consulting
• Takeda Pharmaceuticals – Advisory Board, Speakers bureau
• Sanofi – Advisory Board

 Sahil Khanna, M.B.B.S., M.S.

• Rebioitx / Ferring, Vedanta, and Pfizer –   Research support
• Seres, ProbioTech, Takeda, Niche, and Immuron – Consulting

Target Audience: Wayne State University School of Medicine faculty, staff, medical students, fellow and residents

The Wayne State University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Wayne State University School of Medicine designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit (s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.